Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Clinical Drug Investigation|September 19, 2021
Impact of Body Mass Index on the Efficacy of Biological Therapies in Patients with Psoriasis: A Real-World StudyFederico Pirro, Giacomo Caldarola, Andrea Chiricozzi, et al.
Giornale Italiano Di Dermatologia E Venereologia : Organo Ufficiale, Societa Italiana Di Dermatologia E Sifilografia|June 18, 2020
New JAK inhibitors for the treatment of psoriasis and psoriatic arthritisDario F D'Urso, Andrea Chiricozzi, Federico Pirro, et al.
Expert Opinion on Biological Therapy|November 10, 2020
Comparison of short- and long-term effectiveness of ixekizumab and secukinumab in real-world practiceGiacomo Caldarola, Marco Mariani, Federico Pirro, et al.
The Journal of Dermatological Treatment|July 25, 2020
The impact of COVID-19 pandemic in a cohort of Italian psoriatic patients treated with biological therapiesFederico Pirro, Giacomo Caldarola, Andrea Chiricozzi, et al.
Expert Review of Clinical Immunology|October 26, 2021
Risk of infections in psoriasis: assessment and challenges in daily managementClara De Simone, Maria Concetta Fargnoli, Paolo Amerio, et al.
Dermatologic Therapy|March 16, 2021
Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional studyMaria Esposito, Alessandro Giunta, Paolo Gisondi, et al.
Journal of Clinical Medicine|August 26, 2022
Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb StudyGiovanni Pellacani, Laura Bigi, Aurora Parodi, et al.
Expert Opinion on Biological Therapy|July 19, 2021
Predictive factors of lack of response to adalimumab among bio-naive patients suffering from moderate-to severe psoriasis: analysis of a multicenter data collection in ItalyArianna Zangrilli, Giacomo Caldarola, Nicoletta Bernardini, et al.
Dermatology Practical & Conceptual|March 21, 2025
Risankizumab Versus Secukinumab: A Real-World Efficacy and Cost per Responder Comparison in Patients With Psoriasis in ItalyFederico Pirro, Giacomo Caldarola, Nicoletta Bernardini, et al.
American Journal of Clinical Dermatology|August 17, 2022
Drug Survival of Interleukin (IL)‑17 and IL‑23 Inhibitors for the Treatment of Psoriasis: A Retrospective Multi‑country, Multicentric Cohort StudyTiago Torres, Luis Puig, Ron Vender, et al.
Pageof 1